Candesartan chemical structure
Find information on thousands of medical conditions and prescription drugs.

Candesartan

Candesartan (kan-de-SAR-tan) belongs to the class of medicines called angiotensin II receptor antagonists. It is used to treat high blood pressure (hypertension) and is marketed under the brand name Atacand® (alternative name: Ratacand®) by AstraZeneca. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled.

Candesartan works by blocking the action of a substance in the body that causes blood vessels to tighten. As a result, candesartan relaxes blood vessels. This lowers blood pressure.

Side-effects

By decreasing aldosterone levels, candesartan and related drugs may cause hyperkalemia (high potassium levels in the blood). Supplements containing potassium, which are sometimes taken by patients with high blood pressure, are discouraged.

Some people taking candesartan report dizziness (occurs in 1 out of every 25 persons), blurry vision, lightheadedness, a sore throat or a runny nose. More serious side effects can be fainting, decreased sexual ability, jaundice, severe nausea, fatigue and chest pain.

Contraindications

It is contraindicated in pregnancy, especially in the last six months, preexistent hyperkalemia and a history of drug reactions to other AT II inhibitors.

Read more at Wikipedia.org


[List your site here Free!]


Candesartan reduces cardiovascular death in CHF patients on ACE inhibitor
From Journal of Family Practice, 2/1/04 by Ginger Wiley

McMurray JJV, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771.

* PRACTICE RECOMMENDATIONS

The addition of candesartan (Atacand) to an angiotensin-converting enzyme (ACE) inhibitor and other treatment reduces cardiovascular death and hospital admissions of patients with congestive heart failure (CHF). As in studies conducted with valsartan (Diovan), candesartan added to an ACE inhibitor does not decrease overall mortality. Clinicians should add candesartan to the medical regimen in nonallergic CHF patients with an ejection fraction of 40% or lower who are already on an optimal dose of an ACE inhibitor.

* BACKGROUND

Despite high doses of an ACE inhibitor, some angiotensin II is still produced by the kidney. ARB treatment, in addition to an ACE inhibitor, might offer a benefit. The addition of valsartan to an ACE inhibitor in a previous study decreased cardiovascular mortality but did not affect overall mortality.

A recent study combining valsartan and captopril (Capoten) for patients with a recent myocardial infarction and heart failure showed increased adverse events without any change in survival compared with captopril or valsartan alone. (1) This study evaluated the addition of the ARB candesartan to patients with heart failure already receiving an ACE inhibitor.

* POPULATION STUDIED

The investigators enrolled patients aged 18 years or older with left ventricular ejection fraction of 40% or lower and New York Heart Association functional class II-IV CHF who were on optimal, stable doses of ACE inhibitors. Other variables, such as age, race, comorbidities, and medications were similar to typical family practice patients with CHF.

* STUDY DESIGN AND VALIDITY

Of the 2548 subjects enrolled, 1276 were assigned to receive candesartan and 1272 to receive placebo. Starting doses were 4 to 8 mg once daily, and the dose was doubled every 2 weeks as tolerated until a target dose of 32 mg was reached. Patients were seen at 2 weeks, 4 weeks, 6 weeks, 6 months, and then every 4 months until the end of the trial. The median follow-up was 41 months.

The study was well done. Randomization was computer-generated, both subjects and investigators were blinded to treatment assignment, and allocation was concealed. The analysis was intention-to-treat and included all randomized patients. The patient population was mostly male (79%) and of European decent (90%). The randomization scheme ended up placing more smokers in the placebo group (18.5% vs 15.2%), which could have increased the cardiovascular mortality in this group. Almost all (99.8%) patients were followed completely through the study, with only 4 patients lost to follow-up. (Level of evidence: 1b)

* OUTCOMES MEASURED

The primary outcome was cardiovascular death or unplanned admission to the hospital for worsening CHF. All-cause mortality and the numbers of hospitalizations for any reason were also measured.

* RESULTS

Overall, 483 (37.9%) patients in the candesartan group and 538 (42.3%) in the placebo group experienced the primary outcome of cardiovascular death or unplanned admission to the hospital for worsening CHF (P=.011; number needed to treat [NNT] =23 for 41 months).

Taking the outcomes individually, cardiovascular mortality was lower in the treated patients (23.7% vs 27.3%; NNT=28; 95% confidence interval [CI], 13-200), as was the admission rate due to CHF (24.2% vs 28.0%; NNT=26; 95% CI, 12-90). Unlike a previous study with valsartan, patients receiving an ARB, ACE inhibitor, and beta-blocker did not have a higher mortality than patients not receiving a beta-blocker.

Overall all-cause mortality was not improved with the addition of the ARB, which was approximately 30% in both groups. Almost 1 in 4 (24.2%) patients in the candesartan group and 18.3% in the placebo group discontinued the study medication because of an adverse event or abnormal lab value (P=.0003). By 6 months systolic blood pressure was lowered by 4.6 mm Hg and diastolic blood pressure by 3.0 mm Hg more in the candesartan-treated group (P=.004).

REFERENCE

(1.) Pfeffer MA, McMurray JJK, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1906.

Ginger Wiley, MD, and Charles Cole, MD, Department of Family Practice, University of Virginia Health Sciences Center, Stoney Creek Family Practice, Nellysford, Va. E-mail: cjc4y@virginia.edu.

COPYRIGHT 2004 Dowden Health Media, Inc.
COPYRIGHT 2004 Gale Group

Return to Candesartan
Home Contact Resources Exchange Links ebay